Replimune Group, Inc. is a clinical-stage biotechnology company committed to advancing oncology treatments through immuno-oncology product candidates. With a global reach, its facilities serve across North America and Europe.
Operating in the pharmaceuticals sector, the company specialises in manufacturing immuno-oncology therapies that aim to improve survival rates and quality of life for cancer patients. Derived from its proprietary RPx platform, Replimune Group, Inc. is developing a pipeline of tumour-directed oncolytic immunotherapies targeted at the unmet needs of multiple cancer types.
Learn more about the share price performance of REPL on eToro.